CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2015—Beckman Coulter Diagnostics will distribute four new immunosuppressant drug user defined reagents as part of the company’s therapeutic drugs monitoring menu on its AU family of clinical chemistry systems. The assays, manufactured by Thermo Fisher Scientific, will enable laboratories to deliver vital results for the management of immunosuppressant drug therapy for organ transplant patients, specifically aiding in the management of kidney, liver, and heart transplant patients.
The assays include the QMS Everolimus (EVR), CEDIA Mycophenolic Acid (MPA), QMS Tacrolimus (TAC), and CEDIA Cyclosporine Plus (low range: CSAL, high range: CSAH). These products offer a comprehensive package of reagents, calibrators, and controls and have received clearance for distribution in the U.S., Puerto Rico, and the EU. The assays are available for use on Beckman Coulter’s AU480, AU680, and AU5800 clinical chemistry systems.
Beckman Coulter Diagnostics, 714-993-5321